Jieun Park
Papers
1
Total Citations
12
H-Index
1
About
Dr. Jieun Park is pioneering the frontier of cancer immunotherapy through her innovative work in biohybrid microrobotics and targeted drug delivery. Her research centers on engineering living immune cells—particularly natural killer (NK) cells—as intelligent, active therapeutic vehicles. In her landmark 2024 study, Dr. Park introduced pH-sensitive magnetic nanoparticle-mediated NK-cell-based microrobots, a dual-targeted platform that simultaneously delivers chemotherapeutics and induces pro-inflammatory macrophage polarization. This approach overcomes the critical challenge of weak tumor targeting in adoptive cell therapy by leveraging NK cells’ innate ability to directly induce cancer cell necrosis without prior education. The work has already garnered 12 citations, signaling its rapid impact on the fields of nanomedicine and immunoengineering. By integrating magnetic guidance with pH-responsive drug release, Dr. Park’s system enables precise, spatiotemporal control over both the cellular and molecular components of the tumor microenvironment. Her contributions represent a significant leap toward next-generation cancer immunotherapies that are more effective, less toxic, and inherently smarter—offering a powerful blueprint for combining living cells with synthetic nanomaterials to combat solid tumors.
Research Focus
Key Achievements
Top Papers
- 1